January 1st 2021, 10:00pm
Coronavirus disease 2019 (COVID-19) dominated 2020. This is a look back at how the pandemic evolved and progressed through the year, which closed with the arrival of vaccines, but also continued challenges.
December 31st 2020, 1:00pm
Several economic benefits stem from engaging in care soon after HIV transmission and maintaining viral load suppression, noted Milena Murray, PharmD, MSc, BCIDP, AAHIVP, associate professor, Midwestern University College of Pharmacy.
December 23rd 2020, 12:00pm
The FDA has approved Margenza (margetuximab-cmkb) plus chemotherapy as a treatment option for adults with HER2-postive advanced breast cancer.
December 18th 2020, 3:00pm
Texas Oncology physicians discuss utilization of telemedicine, evaluating trends, barriers, and opportunities in care delivery during the coronavirus disease 2019 pandemic.
December 17th 2020, 2:00pm
Older adults are often at greater risk for adverse events from treatments, but they can also be excluded from randomized controlled trials (RCTs), making it difficult to know if findings are generalizable to this population.
December 17th 2020, 11:00am
In roughly half of cases assessed, physicians underestimated a patients’ risk, according to multiparametric objective risk-assessment tools.
December 11th 2020, 2:00pm
This article describes food allergy–related service utilization and identifies factors associated with guideline-informed care among Medicaid-enrolled US children with food allergy.
December 10th 2020, 6:00pm
Highlands Oncology Group has found the most success getting the word out about its lung cancer screening program by directly engaging with primary care physicians (PCPs), said Joanna Thompson of Highlands Oncology Group.
December 7th 2020, 10:00am
Overall survival from early breast cancer has steadily been increasing; however, simultaneous increases in obesity and obesity-related comorbidities may have contributed to the survival disparity seen between these patient groups.
December 5th 2020, 5:15pm
In the real world, the persistence rate with secukinumab to treat psoriatic arthritis was higher than with ustekinumab.
